Diligence memo · auto-generated · as of July 2, 2026
A28 Therapeutics, Inc.
A28 Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
A28 Therapeutics, Inc. operates in Pharma, based in LA JOLLA.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
A28 Therapeutics, Inc. has raised $1.9M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.9M on 2022-02-01.
Most recent recorded round closed around 2022-02-01.
Valuation (modeled)modeled
Provath models A28 Therapeutics, Inc. at approximately $32M (range $1.4M–$162M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.34× the median modeled value of Seed Pharma companies in 2022–2024 (18 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.4 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 43% of Pharma peers (310 compared).
Modeled value ranks above 50% of those peers.
Closest niche peers: Seal Rock Therapeutics, Inc., Diligent Pharma, Inc., Centaurus Therapeutics, Inc., Pathfinder Oncology, Inc., Arcade Therapeutics, Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.